Mannkind (MNKD) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.25% |
| Dec 31, 2025 | 29.64% |
| Sep 30, 2025 | 27.25% |
| Jun 30, 2025 | 28.04% |
| Mar 31, 2025 | 36.70% |
| Dec 31, 2024 | 45.54% |
| Sep 30, 2024 | 26.09% |
| Jun 30, 2024 | 20.14% |
| Mar 31, 2024 | 31.21% |
| Dec 31, 2023 | 27.27% |
| Sep 30, 2023 | 24.12% |
| Jun 30, 2023 | 20.36% |
| Mar 31, 2023 | 13.47% |
| Dec 31, 2022 | 19.09% |
| Sep 30, 2022 | 23.77% |
| Jun 30, 2022 | 28.75% |
| Mar 31, 2022 | 17.24% |
| Dec 31, 2021 | 25.75% |
| Sep 30, 2021 | 16.18% |
| Jun 30, 2021 | 23.71% |
| Mar 31, 2021 | 8.28% |
| Dec 31, 2020 | -4.10% |
| Sep 30, 2020 | -13.03% |
| Jun 30, 2020 | 4.24% |
| Mar 31, 2020 | -10.85% |
| Dec 31, 2019 | -13.75% |
| Sep 30, 2019 | 18.53% |
| Jun 30, 2019 | -42.44% |
| Mar 31, 2019 | -28.10% |
| Dec 31, 2018 | -39.32% |
| Sep 30, 2018 | -37.16% |
| Jun 30, 2018 | -26.32% |
| Mar 31, 2018 | -17.84% |
| Dec 31, 2017 | -21.00% |
| Sep 30, 2017 | -20.06% |
| Jun 30, 2017 | -16.46% |
| Mar 31, 2017 | -15.13% |
| Dec 31, 2016 | -20.58% |
| Sep 30, 2016 | -14.68% |
| Jun 30, 2016 | -7.43% |
| Mar 31, 2016 | -13.65% |
| Dec 31, 2015 | 0.96% |
| Sep 30, 2015 | -4.87% |